Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 52 от 100

Набира участници Фаза 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Solid Tumor Advanced Solid Tumor Solid Tumor, Adult Metastatic Tumor +24

The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).

Начало: 19.09.2024 Край: 01.05.2029 Възраст: от 18 г.

United States NiKang Therapeutics, Inc. NCT06586957

Набира участници Фаза 1

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Thoracic Tumors Non-small Cell Lung Cancer

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.

Начало: 17.09.2024 Край: 27.10.2031 Възраст: 18–100 г. Лечение

Argentina, Australia, Belgium +16 Amgen NCT06333951

Набира участници Фаза 1

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Pancreatic Ductal Adenocarcinoma Non-small Cell Lung Cancer Colorectal Cancer

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

Начало: 12.09.2024 Край: 01.03.2029 Възраст: от 18 г.

Canada, China, France +6 Eli Lilly and Company NCT06586515

Набира участници Фаза 2

Pinoxin for the Prevention of Radiation-Induced Skin Injury

Cancer Patients Undergoning Radiotherapy

The incidence of radiation-induced skin injury is high, and effective preventive measures are currently lacking. This study evaluates the role of the skin protective agent Pinoxin in preventing skin injury. Patients are randomly assigned into two prospective groups: treatment group and control group. In treatment group, patients will receive Pinoxin treatment. In control group，patients will receive placebo treatment. The rate of grade 2 or greater skin injury will be analyzed.

Начало: 05.09.2024 Край: 31.12.2026 Възраст: от 18 г.

China Fudan University NCT07545720

Набира участници Фаза 1

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

Cancer Breast Cancer Endometrial Cancer Metastatic Cancer +1

The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.

Начало: 22.08.2024 Край: 29.12.2027 Възраст: от 18 г. Лечение

Australia, France, Japan +5 Alterome Therapeutics, Inc. NCT06533059

Набира участници

Characteristics of Intestinal Microbiome Following Pancreatic Surgery

Pancreatic Cancer Microbiota Pancreatoduodenectomy

The goal of this observational study is to learn about intestinal microbiome structure and function in individuals who have undergone a pancreatoduodenectomy and compare to healthy matched controls. The primary objectives of the study are: 1. To explore and describe any differences in the gut microbiota especially Shannon diversity index 2. To conduct functional profiling by exploring and describing any differences in functional metabolites produced in the gut in people having had pancreatoduodenectomy greater than 6 months ago compared to healthy matched controls. Participants will be asked to complete the following: * Three-day food, bowel and medication diary (see Protocol appendix 5) * Gastrointestinal Symptom Rating Scale (see Protocol appendix 6) * Quality of life questionnaire (see Protocol appendix 7) * Stool sample test using Microba Insight TradeMark (a small swab is taken from soiled toilet paper, sealed in a room-temperature storage capsule and mailed to the testing laboratory)

Начало: 01.08.2024 Край: 01.08.2025 Възраст: от 18 г.

Australia Royal Prince Alfred Hospital, Sydney, Australia NCT06319755

Набира участници

RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil

Non-squamous Non-Small Cell Lung Cancer

The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2024.

Начало: 25.07.2024 Край: 30.06.2026 Възраст: от 18 г.

Brazil AstraZeneca NCT06491862

Набира участници Ранна Фаза 1

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

PDL1 Gene Mutation Non Small Cell Lung Cancer Small Cell Lung Cancer ( SCLC ) TNBC, Triple Negative Breast Cancer +5

This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability, biodistribution, radiation dosimetry and preliminary anti-tumour activities of 177Lu-RAD204 in participants with selected solid tumours, to identify the MTDs/ recommended doses of 177Lu-RAD204 for future exploration. The study will consist of a Pre-screening Period (if applicable for PD-L1 testing), a Screening Period of up to 4 weeks, followed by a Phase 0 (Imaging) Period for imaging and dosimetry to 177Lu-RAD204im and a Phase I (Treatment) Period for 177Lu-RAD204tr dose escalation.

Начало: 03.06.2024 Край: 01.12.2027 Възраст: от 18 г. Лечение

Australia Radiopharm Theranostics, Ltd NCT06305962

Набира участници Фаза 1

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Solid Tumor, Adult Bladder Cancer Urothelial Carcinoma Triple-negative Breast Cancer +5

This is an open-label pilot study of a new PET/CT imaging agent MNPR-101-DFO\*-89Zr in patients with solid tumor cancers. These cancers may include bladder/urothelial, triple-negative breast, lung, colorectal, gastric, ovarian, and pancreatic cancers. MNPR-101-DFO\*-89Zr is made of MNPR-101, a humanized IgG1 monoclonal antibody and a radioisotope Zirconium-89. This imaging agent may show where tumors are present in the body using a PET-scan. Participants will be injected with the radioactive tracer once. After injection, participants will have 3 PET-scans. Each PET-scan will take about 30 minutes. The PET-scans are on separate days within 10 days after injection (e.g., 2 hours after injection, plus 3-5 days and 7-10 days after injection). Furthermore, the investigators will take blood samples 6 times (5 mL each). Blood pharmacokinetics (PK) will be measured on Day 1 at 10 min, 1h, 2h, once on Days 3-5, and once on Days 7-10. The study will see if the new imaging agent correctly shows all tumors. In the future, this method may be useful to help predict who will benefit from certain therapies.

Начало: 30.05.2024 Край: 01.04.2026 Възраст: от 18 г. Диагностика

Australia Monopar Therapeutics NCT06337084

Набира участници Фаза 1

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.

Начало: 29.05.2024 Край: 25.02.2029 Възраст: 18–100 г. Лечение

Australia, Belgium, Canada +12 Amgen NCT06360354

Набира участници

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Gastric Cancer

To explore the efficacy and safety of fruquintinib and albumin-paclitaxel combined with or without PD-1 antibody in the second-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma that failed to be treated by anti-PD-1 /PD-L1 regimen

Начало: 15.04.2024 Край: 30.12.2026 Възраст: от 18 г.

China Cancer Institute and Hospital, Chinese Academy of Medic NCT06417892

Набира участници Фаза 3

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Non-Small Cell Lung Cancer

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

Начало: 11.04.2024 Край: 28.12.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +17 AstraZeneca NCT06357533

Набира участници Фаза 1

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Non Small Cell Lung Cancer Triple Negative Breast Cancer Hodgkin Lymphoma Head and Neck Squamous Cell Carcinoma +1

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

Начало: 19.03.2024 Край: 01.05.2027 Възраст: от 18 г.

United States Compass Therapeutics NCT06150664

Набира участници Фаза 1/2

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Advanced Solid Tumors With KRAS G12C Mutations Solid Tumor, Adult Unresectable Solid Tumor Metastatic Solid Tumor +4

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

Начало: 12.02.2024 Край: 01.04.2028 Възраст: от 18 г. Лечение

Australia, South Korea, United States Frontier Medicines Corporation NCT06244771

Набира участници Фаза 1/2

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Advanced Head and Neck Squamous Cell Carcinoma Advanced Esophageal Squamous Cell Carcinoma Cervical Squamous Cell Carcinoma +3

This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers

Начало: 05.02.2024 Край: 01.12.2027 Възраст: от 18 г. Лечение

Australia, Moldova, Singapore +2 Hummingbird Bioscience NCT05910827

Набира участници Фаза 1/2

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Non-Small Cell Lung Cancer, NSCLC KRAS, NRAS, HRAS-mutated NSCLC KRAS G12C-mutated Solid Tumors, Lung Cancer Lung Cancer Stage IV, Advanced Solid Tumor, Cancer +1

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805

Начало: 18.01.2024 Край: 01.12.2028 Възраст: от 18 г. Лечение

Australia, Denmark, France +7 Revolution Medicines, Inc. NCT06162221

Набира участници Фаза 1/2

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Cancer HLA-A*02:01-positive

This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.

Начало: 10.01.2024 Край: 30.11.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Germany +3 Immunocore Ltd NCT06840119

Набира участници Фаза 3

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Advanced Cancer Metastatic Cancer

This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).

Начало: 05.01.2024 Край: 17.01.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +9 Daiichi Sankyo NCT06174987

Набира участници Фаза 2

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

TNBC - Triple-Negative Breast Cancer Breast Cancer

This is an open-label prospective, single institution, Phase II study of pembrolizumab in combination with radiation therapy and CSF-1R inhibition in patients with high-risk TNBC. The primary objective is to assess the pathologic complete response (pCR) rate where pCR is defined as the absence of invasive disease in the breast and lymph nodes at the time of standard of care (SOC) treatment. Secondary objectives include evaluating the change in tumor infiltrating lymphocytes (TILs), safety and tolerability of the combination, progression-free survival, event-free survival, overall survival, and node clearance.

Начало: 17.11.2023 Край: 01.12.2026 Възраст: от 18 г.

United States Stephen Shiao NCT05491226

Набира участници Фаза 3

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

Начало: 16.11.2023 Край: 29.06.2032 Възраст: 18–100 г. Лечение

Argentina, Australia, Austria +35 Amgen NCT05920356

1 … 50 51 52 53 54 … 100